drugset / Trial / NCT03217149

Heliox for Neonate With Acute Respiratory Distress Syndrome (ARDS)

NCT03217149

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Acute respiratory distress syndrome (ARDS) in neonates has been defined, the role of heliox is not clear.This study aimed to determine whether ARDS neonate would benefit from heliox when oxygenation deteriorated on mechanical ventilation and to identify any potential risk factors related to mortality.

Timeline

Start
2017-09-01
Primary completion
2020-08-30
Completion
2020-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Heliox Other / unclassified